CIBC Bancorp USA’s Amicus Therapeutics FOLD Stock Holding History

CIBC Bancorp USA’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,983	Closed	-$217K	–	1977
2026 Q1	$217K	Buy	+14,983	New	+$215K	﹤0.01%	1584
2025 Q3	$234K	Buy	+29,682	New	+$211K	﹤0.01%	1197

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

CIBC Bancorp USA's FOLD Position: Q2 2026 in Review

CIBC Bancorp USA sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 14,983 shares — an estimated $217K sold.

CIBC Bancorp USA first reported a position in FOLD in Q3 2025 and held it in 2 quarters. The position peaked at $234K in Q3 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

CIBC Bancorp USA reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
CIBC Bancorp USA sold 14,983 Amicus Therapeutics shares in Q2 2026, an estimated $217K.
CIBC Bancorp USA first reported a position in Amicus Therapeutics in Q3 2025 and held it in 2 quarters.
CIBC Bancorp USA's Amicus Therapeutics position peaked at $234K in Q3 2025.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.